Anti‐inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.17341 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Fynn Gurski und 10 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Neurology, Department of Neurology, University of Giessen, Giessen, Germany. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Mice, Inbred C57BL, Remyelination, Multiple Sclerosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Purpose FGF, VEGFR‐2 and CSF1R signalling pathways play a key role in the pathogenesis of multiple sclerosis (MS). Selective inhibition of FGFR by infigratinib in MOG 35‐55 ‐induced experimental autoimmune encephalomyelitis (EAE) prevented severe first clinical episodes by 40%; inflammation and neurodegeneration were reduced, and remyelination was enhanced. Multi‐kinase inhibition of FGFR1‐3, CSFR and VEGFR‐2 by fexagratinib (formerly known as AZD4547) may be more efficient in reducing inflammation, neurodegeneration and regeneration in the disease model. Experimental Approach Female C57BL/6J mice were treated with fexagratinib (6.25 or 12.5 mg·kg −1 ) orally or placebo over 10 days either from time of EAE induction (prevention experiment) or onset of symptoms (suppression experiment). Effects on inflammation, neurodegeneration and remyelination were assessed at the peak of the disease (Day 18/20 post immunization) and the chronic phase of EAE (Day 41/42). Key Results In the prevention experiment, treatment with 6.25 or 12.5 mg·kg −1 fexagratinib prevented severe first clinical episodes by 66.7% or 84.6% respectively. Mice treated with 12.5 mg·kg −1 fexagratinib hardly showed any symptoms in the chronic phase of EAE. In the suppression experiment, fexagratinib resulted in a long‐lasting reduction of severe symptoms by 91 or 100%. Inflammation and demyelination were reduced, and axonal density, numbers of oligodendrocytes and their precursor cells, and remyelinated axons were increased by both experimental approaches. Conclusion and Implications Multi‐kinase inhibition by fexagratinib in a well‐tolerated dose of 1 mg·kg −1 in humans may be a promising approach to reduce inflammation and neurodegeneration, to slow down disease progression and support remyelination in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Neurology, Department of Neurology, University of Giessen, Giessen, Germany.
- Institute of Neuropathology, University Medical Centre Göttingen, Göttingen, Germany.
- Institute for Anatomy and Cell Biology, University of Giessen, Giessen, Germany.
- Institute of Anatomy and Cell Biology, University of Würzburg, Würzburg, Germany.
ORCID-Profile: Kian Shirvanchi, Vinothkumar Rajendran
Zitieren
APA
Gurski, F., Shirvanchi, K., Rajendran, V., Rajendran, R., Megalofonou, F. F., Böttiger, G., Stadelmann, C., Bhushan, S., Ergün, S., Karnati, S., & Berghoff, M. (2025). Anti‐inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis. British Journal of Pharmacology. https://doi.org/10.1111/bph.17341
Vancouver
Gurski F, Shirvanchi K, Rajendran V, Rajendran R, Megalofonou FF, Böttiger G, et al. Anti‐inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis. British Journal of Pharmacology. 2025. doi:10.1111/bph.17341
BibTeX
@article{Gurski2025,
author = {Gurski, Fynn and Shirvanchi, Kian and Rajendran, Vinothkumar and Rajendran, Ranjithkumar and Megalofonou, Fevronia-Foivi and Böttiger, Gregor and Stadelmann, Christine and Bhushan, Sudhanshu and Ergün, Süleyman and Karnati, Srikanth and Berghoff, Martin},
title = {Anti‐inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17341}
}
EUVIMED